TGFA and myeloid sarcoma: Given the relative reduction of TGFα in the CSF of MS patients, alongside its negative correlation with disability at the time of relapse, BBB-penetrating intranasal delivery might represent an approach to target CNS-intrinsic autoimmune inflammation.